E275 - Busting Myths About ADHD Medications with Dr. Tim Wilens

Feb 11, 2026

Timothy Wilens, a Harvard psychiatrist and expert in ADHD and addiction medicine, cuts through myths about ADHD medications. He discusses why stigma persists, differences between stimulants and nonstimulants, diversion and misuse patterns, safety concerns, and how clinicians can counter misinformation. Multiple short, focused takes make complex evidence easy to follow.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Delayed Prefrontal Development Explains Dysregulation

Neuroimaging shows delayed prefrontal development and altered circuitry in attention, emotion, and reward.
Timothy Wilens describes about a 1.5-year developmental delay in prefrontal maturation for kids with ADHD.

ADVICE

Begin Treatment With Evidence-Based Stimulants

Start with stimulants because they are the most effective and best-studied first-line agents.
Remain open to non-stimulants since they may address different symptom domains and patient needs.

INSIGHT

Medication Myths Persist Despite Evidence

Common medication myths include short-term/long-term safety concerns and stimulant addiction risk.
Timothy Wilens argues that accumulating evidence largely rebuts many of these myths.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

In this episode, Dr. Andy Cutler talks with Dr. Tim Wilens about enduring myths surrounding ADHD diagnosis and treatment, beginning with why misconceptions about overdiagnosis and misuse continue to shape clinical hesitation. They explore common misunderstandings about ADHD medications—including stimulants versus non-stimulants, concerns about diversion, personality changes, and long-term safety—and contrast stigma-driven narratives with the clinical evidence. The conversation equips clinicians with practical, evidence-based strategies to address patient fears, counter misinformation, and make thoughtful, individualized treatment decisions.

Timothy Wilens, MD, is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders, embedded health care models, and the pharmacotherapy of ADHD across the lifespan.

Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.

Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast

Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp

Stay updated with email alerts and join our conversations on social. Follow us on:

YouTube: https://nei.global/youtube

Instagram: https://nei.global/instagram

LinkedIn: https://nei.global/linkedin

Facebook: https://nei.global/facebook

X: https://nei.global/twitter